NeuroVive Pharmaceutical AB, a company in the pharmaceutical sector, has just created its first French subsidiary in Lyon, supported by the people at Aderly.

NeuroVive, specializing in mitochondrial medicine, develops treatments for cardiovascular and neurological diseases. Through its research on myocardial infarction, the company has developed CicloMulsion, a product that should be marketed in the coming months (currently in phase 3 trials).

The establishment of the company in Lyon is based on the decision to continue its long-term collaboration with Hospices Civils de Lyon and Professor Michel Ovize, a specialist of cardiovascular disease and the director of the OPERA (Organ Protection & Replacement) University Hospital Institute (Investissements d’Avenir).

By creating a subsidiary in France, Neurovive will be able to participate in the RHU (university teaching hospital research) call for proposals, which supports research projects with strong potential for a rapid transfer to industry or society. An application has been filed requesting nearly 10 million euros in funding over a five-year period, associating NeuroVive with Hospices Civils de Lyon and other industrial partners.